

A review of the FDA approval pathway for biosimilars and a real-world example of the use of infliximab

Additional Resources

Patient Resources

FDA Biosimilar Basics for Patients:

- <https://www.fda.gov/drugs/biosimilars/biosimilar-basics-patients>

Healthcare Professional Resources

FDA Biosimilar Overview for Healthcare Professionals:

- <https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals>

FDA Curriculum Materials for Health Care Degree Programs | Biosimilars:

- <https://www.fda.gov/drugs/biosimilars/curriculum-materials-health-care-degree-programs-biosimilars>
- FDA's curriculum materials are intended to help educate healthcare professionals and students to improve understanding of biosimilar products and the regulatory approval pathway in the United States.
 - Provides resource guide for teaching faculty who would like to incorporate topics related to biosimilar products into their curriculum.

FDA Purple Book. Database of Licensed Biological Products:

- <https://purplebooksearch.fda.gov/>

The Center for Biosimilars®:

- <https://www.centerforbiosimilars.com/biosimilar-approvals>
- Provides information on FDA-approved biosimilars, nonproprietary drug names, expected launch dates, number of approved and launched biosimilars, manufacturers, and therapeutic areas

A REVIEW OF THE FDA APPROVAL PATHWAY FOR BIOSIMILARS AND A REAL-WORLD EXAMPLE OF THE USE OF INFLIXIMAB

Additional Resources

References from the Presentation

- Purple Book Database of Licensed Biological Products. FDA. Accessed Jan 12, 2023. <https://purplebooksearch.fda.gov/>
- The Center for Biosimilars® Biosimilar Approvals. AJMC. Last Updated Apr 04, 2023. Accessed May 12, 2023. <https://www.centerforbiosimilars.com/biosimilar-approvals>
- Drugs@FDA: FDA-Approved Drugs. FDA. Accessed May 12, 2023. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
- Overview for Health Care Professionals. FDA. Content current as of Dec 13, 2022. Accessed Dec 26, 2022. <https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals>
- Overview of Biosimilar Products. FDA. Accessed Dec 26, 2022. <https://www.fda.gov/media/151058/download>
- Blandizzi C, Meroni PL, Lapadula G. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clin Ther. 2017;39(5):1026-1039. doi:10.1016/j.clinthera.2017.03.014
- Biosimilars Info Sheet. Variation in Biological Products. FDA. Accessed Dec 28, 2022. <https://www.fda.gov/media/154915/download>
- Nonproprietary Naming of Biological Products: Guidance for Industry. FDA. Published Jan 2017. Accessed Mar 15, 2023. <https://www.fda.gov/files/drugs/published/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf>
- Nancy J. Globus. Center for Biosimilars. Alphabet Soup: The Story Behind Biosimilar Nonproprietary Name Suffixes. The Center for Biosimilars®. Published Aug 8, 2020. Accessed Mar 17, 2023. <https://www.centerforbiosimilars.com/view/alphabet-soup-the-story-behind-biosimilar-nonproprietary-name-suffixes>
- Generic Drug Facts. FDA. Content current as of Nov 1, 2021. Accessed Dec 26, 2022. <https://www.fda.gov/drugs/generic-drugs/generic-drug-facts>
- Biosimilars Info Sheet Level 2: Regulatory and Scientific Concepts. Prescribing Biosimilar and Interchangeable Biosimilar Products. FDA. Accessed Dec 26, 2022. <https://www.fda.gov/media/154917/download>
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. Current through December 2022. Accessed Dec 26, 2022. <https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm>
- Biologics Price Competition and Innovation Act of 2009 (Sections 7001-7003) of the Patient Protection and Affordable Care Act (Public Law No. 111-148). Congress.gov. Accessed May 22, 2023. <https://www.congress.gov/bill/111th-congress/house-bill/3590>

A REVIEW OF THE FDA APPROVAL PATHWAY FOR BIOSIMILARS AND A REAL-WORLD EXAMPLE OF THE USE OF INFLIXIMAB

Additional Resources

- Biosimilar Regulatory Approval Pathway. Biosimilars Info Sheet Level 1: Foundational Concepts. FDA. Accessed Dec 27, 2022. <https://www.fda.gov/media/154914/download>
- Implementation of the Biologics Price Competition and Innovation Act of 2009. FDA. Content current as of Feb 2016. Accessed Dec 27, 2022. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009>
- Biosimilar Regulatory Review and Approval. FDA. Accessed Jan 3, 2023. <https://www.fda.gov/media/151061/download>
- Biosimilars Info Sheet Level 2: Regulatory and Scientific Concepts. Comparative Clinical Studies. FDA. Accessed Jan 3, 2023. <https://www.fda.gov/media/154916/download>
- Bridges SL Jr, White DW, Worthing AB, et al. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. *Arthritis Rheumatol*. 2018;70(3):334-344. doi:10.1002/art.40388
- Biosimilar review and approval. FDA. Content current as of Dec 13, 2022. Accessed Jan 10, 2023. <https://www.fda.gov/drugs/biosimilars/review-and-approval#indication>
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Published Apr 2015. FDA. Content current as of Apr 24, 2020. <https://www.fda.gov/media/82647/download>
- Interchangeable Biological Products. FDA. Accessed Jan 4, 2023. <https://www.fda.gov/media/151094/download>
- Considerations in demonstrating interchangeability with a reference product. Guidance for industry. FDA. Content current as of May 6, 2020. Accessed Jan 4, 2023. <https://www.fda.gov/media/124907/download>
- Assembly Bill A8519. 2021-2022 Legislative Session. Makes permanent certain provisions of law relating to interchangeable biological products. <https://www.nysenate.gov/legislation/bills/2021/a8519>
- The New York State Senate. Chapter 16 Education. Title 8 The Profession. Article 137, Pharmacy. Section 6816-a. When substitution is required. <https://www.nysenate.gov/legislation/laws/EDN/6816-A>
- Bhat S, Altajar S, Shankar D, et al. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. *J Manag Care Spec Pharm*. 2020;26(4):410-416. doi:10.18553/jmcp.2020.26.4.410
- Morris GA, McNicol M, Boyle B, et al. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money. *Inflamm Bowel Dis*. 2022;28(4):531-538. doi:10.1093/ibd/izab110

A REVIEW OF THE FDA APPROVAL PATHWAY FOR BIOSIMILARS AND A REAL-WORLD EXAMPLE OF THE USE OF INFLIXIMAB

Additional Resources

- Shubow S, Sun Q, Nguyen Phan AL, et al. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary. *Clin Pharmacol Ther.* 2023;113(1):37-49. doi:10.1002/cpt.2765
- Edgar BS, Cheifetz AS, Helfgott SM, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. *J Manag Care Spec Pharm.* 2021;27(8):1129-1135. doi:10.18553/jmcp.2021.27.8.1129
- Jørgensen TS, Skougaard M, Asmussen HC, Lee A, Taylor PC, Gudbergensen H, Kristensen LE. Communication Strategies Are Highly Important to Avoid Nocebo Effect When Performing Non-Medical Switch from Originator Product to Biosimilar Product: Danish Results from Applying the Parker Model a Qualitative 3-Step Research Model [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). Accessed March 17, 2023. <https://acrabstracts.org/abstract/communication-strategies-are-highly-important-to-avoid-nocebo-effect-when-performing-non-medical-switch-from-originator-product-to-biosimilar-product-danish-results-from-applying-the-parker-model-a-q/>.
- Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. *Eur J Clin Pharmacol.* 2018;74(5):655-661. doi:10.1007/s00228-018-2418-4
- Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. *Semin Arthritis Rheum.* 2018;47(5):741-748. doi:10.1016/j.semarthrit.2017.10.002
- Odinet JS, Day CE, Cruz JL, Heindel GA. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. *Journal of Managed Care & Specialty Pharmacy.* 2018;24(10):952-959. doi:10.18553/jmcp.2018.24.10.952